+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Metabolic Disorders Therapeutics Market by Treatment Classifications, Disease Type, Therapeutic Areas, Route Of Administration, Patient Demographics, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 183 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968659
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Metabolic Disorders Therapeutics Market grew from USD 69.84 billion in 2023 to USD 75.55 billion in 2024. It is expected to continue growing at a CAGR of 8.35%, reaching USD 122.49 billion by 2030.

Metabolic disorders therapeutics represent a pivotal frontier in modern medicine, addressing complex biochemical imbalances that affect millions globally. In recent years, groundbreaking research, innovative treatment modalities, and a deeper understanding of disease etiology have converged to transform how these conditions are managed. This executive overview lays the foundation for a comprehensive analysis of current trends, key market drivers, and critical therapeutic advancements in metabolic disorders.

The landscape is driven by an amalgamation of cutting-edge scientific research and dynamic regulatory frameworks that continue to shape treatment paradigms. Clinicians and researchers now have a broader spectrum of therapeutic options, which range from traditional pharmacological treatments to emerging gene and enzyme replacement therapies. As patient-centric approaches gain prominence, stakeholders are increasingly seeking clarity on market segmentation, regional dynamics, and the strategic contributions of leading industry players.

Through a detailed examination of clinical outcomes, innovative pipelines, and a commitment to improved patient care, this document sets the stage for a nuanced discussion on how breakthroughs in metabolic disorders therapeutics are not only reshaping patient care but also fostering robust growth within a competitive and rapidly evolving market.

Transformative Shifts in the Therapeutics Landscape

The pace of transformation within the metabolic disorders therapeutics field is unprecedented. Innovations in biotechnology, coupled with evolving clinical practices, have ushered in a substantial shift in treatment approaches and patient management. Regulatory agencies and healthcare professionals now work in tandem to accelerate the development and approval of novel therapies that cater to previously unmet medical needs.

Recent advancements in genetic research have provided profound insights into the underlying mechanisms of metabolic disorders, leading to the development of tailored treatment strategies that enhance efficacy while minimizing adverse effects. The integration of digital health tools and real-world evidence is further amplifying this transformative moment, ensuring that treatment pathways are more patient-specific and outcome-driven.

In parallel, collaborative efforts between research institutions, healthcare organizations, and pharmaceutical companies are driving a more interconnected and innovative environment. This synergy is critical as it encourages knowledge sharing, accelerates clinical trials, and streamlines the transition of therapies from the laboratory to the bedside. The cumulative impact of these transformative shifts is a market that is more adaptive, resilient, and primed for substantial growth in the coming years.

Key Segmentation Insights in Metabolic Disorders Therapeutics

A detailed examination of market segmentation offers valuable insights into the distribution and potential of metabolic disorders therapeutics. When analyzed through the lens of treatment classifications, the market encompasses enzyme replacement therapies, gene therapies, medications and drugs, and small molecule therapy. Each classification presents unique advantages, challenges, and growth opportunities, thereby providing a multifaceted view of therapeutic innovation.

Examining the segmentation based on disease type reveals a spectrum that includes conditions such as Diabetes Mellitus, Gaucher’s Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, Thyroid Disorders, Urea Cycle Disorders, and Wilson's Disease. Within this analysis, special attention is given to Diabetes Mellitus, which is further dissected into gestational diabetes, type 1 diabetes, and type 2 diabetes, as well as to Thyroid Disorders, which are comprehensively studied across hyperthyroidism and hypothyroidism.

Additional layers of segmentation identify key therapeutic areas, namely endocrine disorders, genetic disorders, and nutritional disorders, while the differentiation by route of administration focuses on intravenous, oral, and subcutaneous methods. Insights extend to patient demographics, distinguishing between adult, geriatric, and pediatric patients, as well as considering the environment of end use, whether in clinics, homecare settings, hospitals, or specialty centers. The segmentation analysis is rounded off by exploring the role of distribution channels encompassing hospital pharmacies, online pharmacies, and retail pharmacies. Together, these diverse segmentation perspectives contribute to a holistic understanding of market dynamics.

Based on Treatment Classifications, market is studied across Enzyme Replacement Therapies, Gene Therapies, Medications & Drugs, and Small Molecule Therapy.

Based on Disease Type, market is studied across Diabetes Mellitus, Gaucher’s Disease, Hemochromatosis, Hypercholesterolemia, Mitochondrial Disorders, Phenylketonuria (PKU), Pompe Disease, Thyroid Disorders, Urea Cycle Disorders, and Wilson's Disease. The Diabetes Mellitus is further studied across Gestational Diabetes, Type 1 Diabetes, and Type 2 Diabetes. The Thyroid Disorders is further studied across Hyperthyroidism and Hypothyroidism.

Based on Therapeutic Areas, market is studied across Endocrine Disorders, Genetic Disorders, and Nutritional Disorders.

Based on Route Of Administration, market is studied across Intravenous, Oral, and Subcutaneous.

Based on Patient Demographics, market is studied across Adult Patients, Geriatric Patients, and Pediatric Patients.

Based on End User, market is studied across Clinics, Homecare Settings, Hospitals, and Specialty Centers.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights Shaping the Market

Regional analysis plays a crucial role in understanding market trends and growth trajectories within the metabolic disorders therapeutics sector. Insights derived from key global regions reveal distinct characteristics and emerging opportunities that continue to shape industry strategies. In the Americas, the market is largely driven by a robust healthcare infrastructure and a strong focus on innovative treatments as well as regulatory initiatives that promote fast-tracking of novel therapies.

The combined region of Europe, Middle East & Africa is characterized by a unique blend of mature healthcare systems and diverse patient demographics. This region benefits from long-standing expertise in managing metabolic disorders alongside a growing demand for tailored therapies. Strategic partnerships and government-backed initiatives further enhance this region’s capacity for clinical excellence.

Asia-Pacific, with its rapidly expanding economies, demonstrates significant potential driven by increased healthcare access, rising incomes, and heightened awareness of metabolic conditions. The region's dynamic research environment and progressive regulatory reforms contribute immensely to market expansion and innovation. Collectively, these regional insights underscore the importance of localized strategies that address varying clinical practices, economic conditions, and cultural nuances associated with patient care.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Massachusetts, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Market Growth

A number of leading companies have emerged as pivotal contributors to the development of metabolic disorders therapeutics. Industry giants such as Abbott Laboratories, AbbVie Inc., Acadia Pharmaceuticals Inc., Amgen Inc., Amicus Therapeutics, Inc., and Astellas Pharma Inc. have significantly advanced research and development efforts in this field.

Companies including AstraZeneca plc, Bayer AG, Biocon Limited, BioMarin Pharmaceutical Inc., and Boehringer Ingelheim International GmbH continue to innovate by launching new therapies and expanding treatment indications. CHIESI Farmaceutici S.p.A., Dr. Reddy’s Laboratories Ltd., and Eli Lilly and Company further cement their roles as leading contributors by prioritizing patient-centric solutions and investing heavily in translational research.

Other notable names such as F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lupin Limited, and Luye Pharma Group Ltd drive continuous improvement in clinical outcomes. The market is also significantly influenced by Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., and Pfizer Inc., as they leverage technological breakthroughs to enhance therapy efficacies. Recordati Industria Chimica e Farmaceutica S.p.A, Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd. further strengthen the competitive landscape by actively engaging in strategic collaborations and expanding their global footprints. This collective industry effort underpins a dynamic, forward-thinking market poised for continued innovation and growth.

The report delves into recent significant developments in the Metabolic Disorders Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Acadia Pharmaceuticals Inc., Amgen Inc., Amicus Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Biocon Limited, BioMarin Pharmaceutical Inc., Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.p.A., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Johnson & Johnson Services, Inc., Lupin Limited, Luye Pharma Group Ltd, Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Otsuka Holdings Co., Ltd., Pfizer Inc., Recordati Industria Chimica e Farmaceutica S.p.A, Sanofi S.A., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Torrent Pharmaceuticals Ltd..

Actionable Recommendations for Industry Leaders

Industry leaders must adopt a proactive approach in navigating the evolving complexities of metabolic disorders therapeutics. It is essential to continually invest in advanced research and foster collaborative initiatives that connect academic institutions, biotech firms, and clinical experts. Emphasizing translational medicine and real-world evidence can expedite the validation and rollout of next-generation therapies.

Leaders should focus on integrating robust data analytics into their operational strategies. By harnessing predictive insights and employing advanced modeling techniques, organizations can better anticipate market shifts and tailor treatment strategies more effectively. An agile approach to product development and market entry is key, ensuring that regulatory, manufacturing, and distribution challenges are met with precision and readiness.

Furthermore, reinforcing strategic partnerships and forming alliances within the healthcare ecosystem is critical. Such collaborations not only enhance resource sharing but also streamline the journey from research discovery to commercial success. Ultimately, a commitment to innovation, patient-centricity, and operational excellence will serve as the cornerstone for sustained competitive advantage in this rapidly evolving sector.

The exploration of metabolic disorders therapeutics offers a compelling narrative of innovation, adaptation, and collaboration. Through a detailed look at market segmentation, regional dynamics, and key industry players, it is evident that the sector is at a transformative juncture. The integration of advanced research methodologies with real-world data continues to redefine treatment paradigms, delivering improved outcomes and enhanced quality of life for patients across demographics.

As the market evolves, transparency in data sharing, increased investment in R&D, and enhanced cross-industry collaboration will remain crucial. This transformative shift, marked by both technological advancements and strategic realignments, underlines the robust growth trajectory of the sector. In reflecting on these trends, stakeholders and decision-makers are encouraged to adopt adaptive, forward-thinking strategies that leverage emerging technologies and optimized market insights to drive sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Shifting lifestyle and dietary patterns contributing to increased incidence of metabolic disorders
5.1.1.2. Rising government initiatives and support for metabolic disorders research
5.1.2. Restraints
5.1.2.1. Concerns associated with product recall and adverse findings in medication
5.1.3. Opportunities
5.1.3.1. Technological advancements in CRISPR-Cas9 and other genome-editing tools for treating metabolic disorders
5.1.3.2. Growing potential with increasing collaborations and investments among pharmaceutical companies and healthcare providers
5.1.4. Challenges
5.1.4.1. Issues related to patent expirations and the complexity of obtaining and maintaining intellectual property
5.2. Market Segmentation Analysis
5.2.1. Treatment Classifications: Increasing benefits of metabolic disorders therapeutics for gene therapies
5.2.2. Disease Type: Proliferating significance of oral medications for treatment of diabetes mellitus
5.2.3. Therapeutic Areas: Growing potential of metabolic disorders therapeutics for the treatment of endocrine disorders
5.2.4. Route Of Administration: Significant advantages of intravenous for drugs that are poorly absorbed orally
5.2.5. Patient Demographics: Increasing application of metabolic disorders therapeutics in adult patients owing to preventing progression through lifestyle modifications
5.2.6. End User: Extending usage of metabolic disorders medications in clinics for small private practices to large multi-specialty facilities
5.2.7. Distribution Channel: Rising popularity of online pharmacies owing to convenience and availability of options
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Metabolic Disorders Therapeutics Market, by Treatment Classifications
6.1. Introduction
6.2. Enzyme Replacement Therapies
6.3. Gene Therapies
6.4. Medications & Drugs
6.5. Small Molecule Therapy
7. Metabolic Disorders Therapeutics Market, by Disease Type
7.1. Introduction
7.2. Diabetes Mellitus
7.2.1. Gestational Diabetes
7.2.2. Type 1 Diabetes
7.2.3. Type 2 Diabetes
7.3. Gaucher’s Disease
7.4. Hemochromatosis
7.5. Hypercholesterolemia
7.6. Mitochondrial Disorders
7.7. Phenylketonuria (PKU)
7.8. Pompe Disease
7.9. Thyroid Disorders
7.9.1. Hyperthyroidism
7.9.2. Hypothyroidism
7.10. Urea Cycle Disorders
7.11. Wilson's Disease
8. Metabolic Disorders Therapeutics Market, by Therapeutic Areas
8.1. Introduction
8.2. Endocrine Disorders
8.3. Genetic Disorders
8.4. Nutritional Disorders
9. Metabolic Disorders Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
9.4. Subcutaneous
10. Metabolic Disorders Therapeutics Market, by Patient Demographics
10.1. Introduction
10.2. Adult Patients
10.3. Geriatric Patients
10.4. Pediatric Patients
11. Metabolic Disorders Therapeutics Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Homecare Settings
11.4. Hospitals
11.5. Specialty Centers
12. Metabolic Disorders Therapeutics Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Americas Metabolic Disorders Therapeutics Market
13.1. Introduction
13.2. Argentina
13.3. Brazil
13.4. Canada
13.5. Mexico
13.6. United States
14. Asia-Pacific Metabolic Disorders Therapeutics Market
14.1. Introduction
14.2. Australia
14.3. China
14.4. India
14.5. Indonesia
14.6. Japan
14.7. Malaysia
14.8. Philippines
14.9. Singapore
14.10. South Korea
14.11. Taiwan
14.12. Thailand
14.13. Vietnam
15. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market
15.1. Introduction
15.2. Denmark
15.3. Egypt
15.4. Finland
15.5. France
15.6. Germany
15.7. Israel
15.8. Italy
15.9. Netherlands
15.10. Nigeria
15.11. Norway
15.12. Poland
15.13. Qatar
15.14. Russia
15.15. Saudi Arabia
15.16. South Africa
15.17. Spain
15.18. Sweden
15.19. Switzerland
15.20. Turkey
15.21. United Arab Emirates
15.22. United Kingdom
16. Competitive Landscape
16.1. Market Share Analysis, 2023
16.2. FPNV Positioning Matrix, 2023
16.3. Competitive Scenario Analysis
16.3.1. Entero Therapeutics and Journey Therapeutics announce reverse merger to expand precision oncology and metabolic disorders therapies
16.3.2. Chiesi Global Rare Diseases publishes phase 3 BRIGHT study results for pegunigalsidase alfa in fabry disease
16.3.3. Sagimet's Denifanstat granted FDA advance therapy designation for MASH
16.3.4. Amneal and Metsera collaborate to advance therapies for mbesity and Metabolic diseases
16.3.5. Genespire secures USD 52.1m for gene therapy trial targeting rare metabolic disorder
16.3.6. HAYA Therapeutics collaborates with Eli Lilly to target obesity and metabolic disorders using advanced rNA platform
16.3.7. Roche acquires Carmot Therapeutics to advance in metabolic disease treatments
16.3.8. ILBS and INSERM partner for advancements in metabolic disorder therapeutics
16.3.9. Fractyl Health expands metabolic therapeutics pipeline with advanced clinical studies and preclinical results
16.3.10. Marea Therapeutics launches with USD 190 million to develop next-gen cardiometabolic treatments
16.3.11. Metsera strategic launch to innovate obesity and metabolic disease therapies
16.3.12. Orchard Therapeutics U.S. launch of Lenmeldy for treating early-onset metachromatic leukodystrophy
16.3.13. BioAge secures USD 170 million in Series D to advance obesity and metabolic therapies
16.3.14. MIT secures USD 65.67 million for innovative metabolic disorder treatments
16.3.15. Novo Nordisk collaborates with Omega Therapeutics and Cellarity on metabolic disorder innovations
16.3.16. Chiesi Farmaceutici to acquire Amryt Pharma, enhancing rare disease therapeutics portfolio
16.4. Strategy Analysis & Recommendation
16.4.1. F. Hoffmann-La Roche Ltd
16.4.2. Lupin Limited
16.4.3. Eli Lilly and Company
16.4.4. Pfizer Inc.
List of Figures
FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2030 (%)
FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2030 (%)
FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 25. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 29. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 30. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 31. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENZYME REPLACEMENT THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MEDICATIONS & DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SMALL MOLECULE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GAUCHER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEMOCHROMATOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY MITOCHONDRIAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PHENYLKETONURIA (PKU), BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY POMPE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPOTHYROIDISM, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY UREA CYCLE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY WILSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ENDOCRINE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY NUTRITIONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 80. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 81. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 82. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 83. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 84. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 85. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 86. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 88. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 89. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 91. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 92. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 93. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 95. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 99. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 100. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 101. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 102. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 104. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 107. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 108. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 109. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 110. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 111. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 112. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 117. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 118. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 120. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 121. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 122. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 126. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 127. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 128. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 129. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 130. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 131. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 133. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 135. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 136. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 137. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 138. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 139. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 140. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 141. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 142. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 145. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 147. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 148. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 149. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 150. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 151. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 154. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 155. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 156. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 157. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 158. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 159. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 162. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 163. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 164. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 165. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 166. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 167. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 169. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 172. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 173. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 174. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 175. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 176. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 177. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 178. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 181. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 183. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 185. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 187. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 189. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 190. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 191. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 192. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 193. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 194. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 195. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 196. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 199. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 200. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 201. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 202. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 203. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 205. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 206. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 207. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 208. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 210. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 211. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 212. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 214. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 217. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 219. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 220. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 221. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 222. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 223. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 235. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 236. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 237. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 238. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 239. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 240. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 242. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 245. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 247. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 248. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 249. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 251. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 253. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 254. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 255. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 256. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 257. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 258. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 259. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 260. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 262. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 263. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 264. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 265. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 267. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 269. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 270. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 271. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 272. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 274. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 275. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 276. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 278. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 281. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 282. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2018-2030 (USD MILLION)
TABLE 283. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2018-2030 (USD MILLION)
TABLE 284. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
TABLE 285. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 287. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2018-2030 (USD MILLION)
TABLE 290. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 291. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages183
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 75.55 Billion
Forecasted Market Value ( USD ) by 2030 $ 122.49 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Metabolic Disorder Therapeutics - Global Strategic Business Report - Product Image

Metabolic Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 94 Pages
  • Global
From
Peptide Based Metabolic Disorders Therapeutics Market Report 2024 - Product Image

Peptide Based Metabolic Disorders Therapeutics Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Amino Acid Metabolism Disorders Treatment Market by Treatment, Indication, End-User - Global Forecast 2025-2030 - Product Image

Amino Acid Metabolism Disorders Treatment Market by Treatment, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Endocrinology Drugs Market by Therapy Area (Adrenal Disorders, Diabetes, Growth Disorders), Drug Class (Calcitonin Peptides, Growth Hormone, Insulin), Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030 - Product Image

Endocrinology Drugs Market by Therapy Area (Adrenal Disorders, Diabetes, Growth Disorders), Drug Class (Calcitonin Peptides, Growth Hormone, Insulin), Mode of Administration, Patient Age Group, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From

About the Metabolic Disorder Drug Market

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss. The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.